Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma (SABLOR)
A Phase Ⅲ Randomized Study Systemic Treatment Alone Versus Systemic Treatment Plus Stereotactic Abative Body Radiotherapy for Patients With Oligometastatic Renal Cell Carcinoma: SABLOR Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Won Park, M.D., Ph.D.
- Phone Number: +82-2-3410-2616
- Email: wonro.park@samsung.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
Contact:
- Won Park, M.D., Ph.D.
- Phone Number: +82-2-3410-2616
- Email: wonro.park@samsung.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with metastatic renal cell carcinoma classified within the ESTRO/EORTC classification system as having ≤ 5 metastases, ≤ 3 metastatic organs, and meeting criteria for new, recurrent, or induced metastases.
- Patients aged 20 to 80 years.
- Patients with individual metastases ≤ 5 cm in longest diameter.
- Patients with primary tumors surgically removed or scheduled for surgery.
- Patients histologically diagnosed with clear cell carcinoma.
- Patients with ECOG performance status 0-1.
- Patients with normal major organ function and bone marrow function meeting specific criteria: WBC ≥ 2,000/μL, neutrophils ≥ 1,000/μL, platelets ≥ 50,000/μL.
- Patients who understand the contents of the informed consent form, voluntarily consent to participate in the study, and sign the informed consent form.
- Patients who agree to use contraception from the time of signing the consent form until 1 year after the last standard systemic therapy.
- Breastfeeding women who agree to stop breastfeeding for at least 5 months after the last standard systemic therapy.
- Patients with visible tumors outside the scope of tumor removal surgery (surgical therapy) for metastatic lesions.
Exclusion Criteria:
- Patients with total bilirubin > 3.6 mg/dL.
- Patients with AST >160 U/L, ALT > 165 U/L.
- Patients unable to maintain position for partial nephrectomy radiotherapy.
- Patients with a history of radiotherapy to metastatic renal cell carcinoma or surrounding areas.
- Patients with confirmed brain, peritoneal, or pleural metastases.
- Patients diagnosed with another solid tumor and treated within 2 years or with residual lesions.
- Patients who do not consent to participate in the study.
- Pregnant patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: A group
Only standard treatment is administered.
The standard treatment includes targeted cancer therapy, immunotherapy, or monotherapy with each therapeutic agent.
|
|
|
Experimental: B group
This group receives concurrent partial nephrectomy radiotherapy for all metastatic lesions in addition to standard treatment.
|
Patients will receive treatment for one to two weeks, one to five times per region.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
1-year progression-free survival rate
Time Frame: One year after completion of enrollment
|
Compare free survival between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
|
One year after completion of enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Local control rate for radiation therapy site at one year
Time Frame: One year after radiation completion of each participant
|
Compare Local control rate between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
|
One year after radiation completion of each participant
|
|
Grade 3 acute adverse event
Time Frame: three to six months after study treatment
|
Compare acute adverse events according to CTCAE V5.0 between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
|
three to six months after study treatment
|
|
Grade 3 chronic adverse event
Time Frame: one year to three years after radiation completion
|
Compare chronic adverse events according to CTCAE V5.0 between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
|
one year to three years after radiation completion
|
|
Overall survival rate
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
|
Compare Overall survival rate between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Neoplasms
- Carcinoma, Renal Cell
Other Study ID Numbers
Other Study ID Numbers
- SMC 2023-04-044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.